Related Experiment Video

Updated: Jun 20, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Inhibiting PI3K as a therapeutic strategy against cancer

Luis Paz-Ares1, Carmen Blanco-Aparicio, Rocío García-Carbonero

  • 1Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|September 25, 2009
PubMed

Insights

Phosphoinositide 3-kinase (PI3K) is crucial for cell functions and cancer. PI3K inhibitors show promise as anticancer therapies, with early in vivo results supporting their development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Class I PI3K (Phosphoinositide 3-kinase) are lipid kinases regulating cell proliferation, apoptosis, and metabolism.
  • PI3K isoforms are frequently amplified in various cancers.
  • The PI3Kalpha catalytic subunit (PIK3CA) is often mutated in tumors, and PI3K mediates oncogenic signaling via HER2 and Ras.

Purpose of the Study:

  • To review the PI3K pathway.
  • To discuss the pharmacological results of PI3K inhibition in cancer therapy.

Main Methods:

  • Literature review of PI3K pathway and PI3K inhibitors.
  • Analysis of in vivo and pharmacological data for PI3K inhibitors.

Main Results:

  • PI3K pathway is implicated in essential cellular functions and cancer development.
  • PI3K inhibitors are emerging as a promising therapeutic strategy.
  • Early in vivo studies demonstrate the potential of PI3K inhibitors in preclinical cancer models.

Conclusions:

  • PI3K is a validated target for anticancer drug discovery.
  • PI3K inhibitors represent a developing class of anticancer therapeutics.
  • Further research and clinical trials are warranted to optimize PI3K inhibitor therapy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...